Alembic receives USFDA final approval for Nifedipine Extended-Release Tablets
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes
The pre-approval inspection of USFDA was completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited
The company had responded to the agency and carried out the required corrective actions.
The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022
The product is expected to be launched by Q4 FY23.
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company is focussed on increasing the capacity utilizations while controlling costs
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Subscribe To Our Newsletter & Stay Updated